Wed: Ormat, NICE, Perrigo drag market down
- ByGlobes-
Dual listed tech companies led the TASE down today but the banks bucked the market.
Dual listed tech companies led the TASE down today but the banks bucked the market.
Perrigo rose strongly on news it had sold its generic division but Ormat continues its plunge.
Perrigo Q4 consolidated net sales were $1.3B, a decrease of 2.5% vs. previous year, misses consensus by $40M.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Sell | Strong Sell |
| Summary | Strong Sell | Sell | Strong Buy | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 8.05 | 7.90 | +0.05 | +0.63% | 6.02M | Lagos | |||
| 160.00 | 160.00 | 160.00 | -10.00 | -5.88% | 1.04M | Lagos | |||
| 31.05 | 31.05 | 30.80 | +0.05 | +0.16% | 4.69M | Lagos | |||
| 24.90 | 25.40 | 24.70 | -0.40 | -1.58% | 66.50M | Lagos | |||
| 0.66 | 0.00 | 0.00 | -0.01 | -1.49% | 73.55K | Lagos | |||
| 67.50 | 67.50 | 67.50 | -7.25 | -9.70% | 170.89K | Lagos | |||
| 18.85 | 18.85 | 18.85 | -0.05 | -0.26% | 27.29K | Lagos | |||
| 5.90 | 5.90 | 5.90 | -0.42 | -6.65% | 1.81K | Lagos | |||
| 43.85 | 40.00 | 40.00 | +3.85 | +9.62% | 6.96M | Lagos | |||
| 0.85 | 0.00 | 0.00 | +0.040 | +4.94% | 7.84M | Lagos | |||
| 0.20 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 86.00 | 86.00 | 86.00 | -7.00 | -7.53% | 102.73K | Lagos | |||
| 8.05 | 8.00 | 7.90 | +0.20 | +2.56% | 11.74M | Lagos | |||
| 27.30 | 27.30 | 27.30 | +0.30 | +1.11% | 187.50K | Lagos | |||
| 18.35 | 18.35 | 18.35 | -0.45 | -2.39% | 276.50K | Lagos |
Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.